WO2015012175A1 - Médicament de diagnostic et médicament thérapeutique pour le cancer du poumon à petites cellules - Google Patents

Médicament de diagnostic et médicament thérapeutique pour le cancer du poumon à petites cellules Download PDF

Info

Publication number
WO2015012175A1
WO2015012175A1 PCT/JP2014/068937 JP2014068937W WO2015012175A1 WO 2015012175 A1 WO2015012175 A1 WO 2015012175A1 JP 2014068937 W JP2014068937 W JP 2014068937W WO 2015012175 A1 WO2015012175 A1 WO 2015012175A1
Authority
WO
WIPO (PCT)
Prior art keywords
nsr100
mir
small cell
lung cancer
cell lung
Prior art date
Application number
PCT/JP2014/068937
Other languages
English (en)
Japanese (ja)
Inventor
正仁 下條
Original Assignee
学校法人関西医科大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 学校法人関西医科大学 filed Critical 学校法人関西医科大学
Priority to JP2015528247A priority Critical patent/JP6467580B2/ja
Publication of WO2015012175A1 publication Critical patent/WO2015012175A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un nouveau gène marqueur du cancer du poumon à petites cellules (gène nSR100) ainsi qu'un procédé de détection du cancer du poumon à petites cellules, un médicament de diagnostic du cancer du poumon à petites cellules et un médicament thérapeutique du cancer du poumon à petites cellules utilisant ce gène.
PCT/JP2014/068937 2013-07-22 2014-07-16 Médicament de diagnostic et médicament thérapeutique pour le cancer du poumon à petites cellules WO2015012175A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015528247A JP6467580B2 (ja) 2013-07-22 2014-07-16 小細胞肺がんの診断薬及び治療薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013151475 2013-07-22
JP2013-151475 2013-07-22

Publications (1)

Publication Number Publication Date
WO2015012175A1 true WO2015012175A1 (fr) 2015-01-29

Family

ID=52393218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/068937 WO2015012175A1 (fr) 2013-07-22 2014-07-16 Médicament de diagnostic et médicament thérapeutique pour le cancer du poumon à petites cellules

Country Status (2)

Country Link
JP (1) JP6467580B2 (fr)
WO (1) WO2015012175A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020027227A1 (fr) 2018-07-31 2020-02-06 国立大学法人大阪大学 Agent thérapeutique contre le cancer du poumon à petites cellules contenant un oligonucléotide
CN111926080A (zh) * 2014-06-18 2020-11-13 东丽株式会社 肺癌的检测试剂盒或装置以及检测方法
WO2022181807A1 (fr) * 2021-02-25 2022-09-01 国立大学法人大阪大学 Oligonucléotide pour induire le saut de n-exons pendant le traitement des précurseurs de l'arnm rest
CN112513062B (zh) * 2018-07-31 2024-05-10 国立大学法人大阪大学 含有寡聚核苷酸的小细胞肺癌治疗药

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502115A (ja) * 2005-07-27 2009-01-29 オンコセラピー・サイエンス株式会社 小細胞肺癌の診断方法
WO2011076144A1 (fr) * 2009-12-24 2011-06-30 Fudan University Compositions et méthodes de profilage du cancer du poumon par expression de microarn dans le plasma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502115A (ja) * 2005-07-27 2009-01-29 オンコセラピー・サイエンス株式会社 小細胞肺癌の診断方法
WO2011076144A1 (fr) * 2009-12-24 2011-06-30 Fudan University Compositions et méthodes de profilage du cancer du poumon par expression de microarn dans le plasma

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DU L. ET AL.: "MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs", J. EXP. CLIN. CANCER RES., vol. 29, no. 75, 2010, pages 1 - 12 *
GURROLA-DIAZ C. ET AL.: "Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor alphal subunit in small- cell lung cancer cells", ONCOGENE, vol. 22, no. 36, 2003, pages 5636 - 5645 *
ORTUNO-PINEDA C. ET AL.: "Binding of hnRNP H and U2AF65 to respective G-codes and a poly- uridine tract collaborate in the N50-5'ss selection of the REST N exon in H69 cells", PLOS ONE, vol. 7, no. 7, 2012, pages 1 - 11 *
RAJ B. ET AL.: "Cross-regulation between an alternative splicing activator and a transcription repressor controls neurogenesis", MOL. CELL, vol. 43, no. 5, 2011, pages 843 - 850, XP028279235, DOI: doi:10.1016/j.molcel.2011.08.014 *
SHIMOJO M. ET AL.: "The small cell lung cancer- specific isoform of RE1-silencing transcription factor (REST) is regulated by neural-specific Ser/Arg repeat-related protein of 100 kDa (nSR100", MOL. CANCER RES., vol. 11, no. 10, 2013, pages 1258 - 1268 *
ZHENG D. ET AL.: "Plasma microRNAs as novel biomarkers for early detection of lung cancer", INT. J. CLIN. EXP. PATHOL., vol. 4, no. 6, 2011, pages 575 - 586 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111926080A (zh) * 2014-06-18 2020-11-13 东丽株式会社 肺癌的检测试剂盒或装置以及检测方法
WO2020027227A1 (fr) 2018-07-31 2020-02-06 国立大学法人大阪大学 Agent thérapeutique contre le cancer du poumon à petites cellules contenant un oligonucléotide
CN112513062A (zh) * 2018-07-31 2021-03-16 国立大学法人大阪大学 含有寡聚核苷酸的小细胞肺癌治疗药
JPWO2020027227A1 (ja) * 2018-07-31 2021-08-10 国立大学法人大阪大学 オリゴヌクレオチドを含有する小細胞肺癌治療薬
US20210277398A1 (en) * 2018-07-31 2021-09-09 Osaka University Small cell lung cancer therapeutic agent containing oligonucleotide
EP3831837A4 (fr) * 2018-07-31 2023-06-14 Osaka University Agent thérapeutique contre le cancer du poumon à petites cellules contenant un oligonucléotide
US11866705B2 (en) 2018-07-31 2024-01-09 Osaka Univerity Small cell lung cancer therapeutic agent containing oligonucleotide
JP7473113B2 (ja) 2018-07-31 2024-04-23 国立大学法人大阪大学 オリゴヌクレオチドを含有する小細胞肺癌治療薬
CN112513062B (zh) * 2018-07-31 2024-05-10 国立大学法人大阪大学 含有寡聚核苷酸的小细胞肺癌治疗药
WO2022181807A1 (fr) * 2021-02-25 2022-09-01 国立大学法人大阪大学 Oligonucléotide pour induire le saut de n-exons pendant le traitement des précurseurs de l'arnm rest

Also Published As

Publication number Publication date
JPWO2015012175A1 (ja) 2017-03-02
JP6467580B2 (ja) 2019-02-13

Similar Documents

Publication Publication Date Title
KR101271964B1 (ko) 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
TWI816712B (zh) 癌促進因子表現抑制劑的有效成分之篩選用試藥及其篩選方法、癌之預防或治療劑的有效成分之篩選用試藥及其篩選方法、癌促進因子表現抑制劑及癌之預防或治療劑
US20070253954A1 (en) Epha4 As Therapeutic Target Of Prc And Pdaca
EP2611933A1 (fr) Procédé de pronostic de la progression du cancer
JP2008530974A (ja) 乳癌関連遺伝子ｚｎｆｎ３ａ１
JP6467580B2 (ja) 小細胞肺がんの診断薬及び治療薬
JP2023098926A (ja) Ｔｕｔ４／７発現調節因子を含む癌予防又は治療用薬学的組成物
KR101315570B1 (ko) 간암 진단 마커 및 치료제로서의 ｎｌｋ
KR101133243B1 (ko) 암의 진단 및 치료를 위한 ｅＩＦ３ｍ의 용도
EP3321377B1 (fr) Procédé pour déterminer la sensibilité à un inhibiteur simultané contre la parp et la tankyrase
JP6005272B2 (ja) 胃癌診断及び治療のためのａｄｃｙ３の用途
US11510911B2 (en) Method for prediction of susceptibility to sorafenib treatment by using SULF2 gene, and composition for treatment of cancer comprising SULF2 inhibitor
EP2436694B1 (fr) Nouvelle protéine gpcr et son utilisation
KR20230088634A (ko) 간암 특이적 바이오 마커 및 이의 용도
KR101793175B1 (ko) Lcn2 유전자를 이용한 소라페닙 치료에 대한 감수성 예측방법 및 lcn2 저해제를 포함하는 암 치료용 조성물
JPWO2006112401A1 (ja) 癌治療用組成物
KR101083562B1 (ko) Ｆｌｊ２５４１６ 유전자의 신규한 용도
JP6839707B2 (ja) Ｇｐｒ１６０を過剰発現する癌の予防、診断および治療
KR20130137562A (ko) 폐암 진단 및 치료를 위한 표적 단백질
KR20190090623A (ko) 전암성 병변에서 조기 간암을 진단 및 예측할 수 있는 바이오 마커 및 이의용도
KR102270926B1 (ko) Banf1, plod3 또는 sf3b4의 억제제를 유효성분으로 포함하는 간암의 예방 및 치료용 조성물
CN108456249B (zh) 变异型α-辅肌动蛋白-4的抗体
WO2011014872A2 (fr) Compositions et procédés de diagnostic, traitement ou prévention de néoplasies
KR101385783B1 (ko) 간암 진단 마커 및 치료제로서의 ｄｂｃ１
KR20180092135A (ko) 대장암 및 직장암의 예방, 진단 또는 치료를 위한 ｖｌｄｌｒ의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14829416

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015528247

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14829416

Country of ref document: EP

Kind code of ref document: A1